Kang Ding, PhD | Chinese Academy of Medical Sciences; Weiku Zhang, PhD; Jiekun Xu, PhD; Jun He, PhD; Yu Yan, PhD
Competition Sponsor: Chinese Academy of Medical Sciences
Awardee Year: 2025
Chronic kidney disease (CKD) is a complex clinical syndrome caused by various reasons, which lasts for more than three months with abnormal renal structure or function and various related metabolic disorders. Its harm is serious, and the incidence rate is increasing year by year. At present, there are no targeted treatment measures for CKD, and clinical treatment mainly adopts strategies such as controlling the primary disease, eliminating risk factors, and symptomatic treatment to treat CKD. It is urgent to develop new therapeutic drugs for CKD. Our team’s research found that jolkinolide B in Euphorbia fischeriana Steud. exhibited significant anti-inflammatory and anti-renal fibrosis effects. It can effectively reduce renal inflammation, decrease collagen fiber deposition in renal interstitium, alleviate renal tubular dilation, delay renal fibrosis, and alleviate renal pathological damage. At present, the extraction and separation process in the laboratory can obtain jolkinolide B with a purity greater than 99%. Furthermore, in the single dose toxicity test on mice, jolkinolide B has a high level of safety. Our team will conduct research on the pharmacy, pharmacology, pharmacokinetics, and safety evaluation of jolkinolide B in accordance with the requirements of the Drug Registration Management Measures, improve the preclinical research of jolkinolide B raw materials and preparations, and lay the foundation for its development as a therapeutic drug for CKD.